Abstract Number: 0110 • ACR Convergence 2020
Does Urate Directly Influence Bone Turnover? Randomized Controlled Trial of Inosine Supplementation
Background/Purpose: Observational studies have reported that serum urate positively correlates with bone mineral density (BMD) and that hyperuricaemia is protective for the development of osteoporosis…Abstract Number: 0690 • ACR Convergence 2020
AR882, a Potent and Selective Uricosuric Agent, Significantly Reduced Serum Urate in Patients with Gout in a Phase 2a Study
Background/Purpose: AR882 is a potent and selective uric acid transporter 1 (URAT1) inhibitor under development for the treatment of hyperuricemia or gout. Phase 1 single…Abstract Number: 0648 • ACR Convergence 2020
Dual Energy CT Has Additional Prognostic Value over Clinical Measures in Gout Including Tophi: Best Evidence Synthesis
Background/Purpose: Dual Energy CT Scan (DECT) can detect monosodium urate crystals in joints and periarticular tissues. EULAR gout guidelines (Richette, 2020) recognized DECT's value in…Abstract Number: 0951 • ACR Convergence 2020
The Comparative Effect of Exposure to Various Risk Factors on the Risk of Hyperuricaemia: Diet Has a Weak Causal Effect
Background/Purpose: Prevention of hyperuricaemia (HU) is critical to the prevention of gout. Therefore, understanding the causal relationships and relative contributions of various risk factors to…Abstract Number: 0649 • ACR Convergence 2020
A Multicenter, Open-Label, Efficacy and Safety Study of Pegloticase in Patients with Uncontrolled Gout Who Have Undergone Kidney Transplantation: Early Data Report
Background/Purpose: Gout’s high prevalence in kidney transplant (KT) recipients has been associated with heavy residual urate burden, decreased urate excretion related to reduced renal function,…Abstract Number: 0952 • ACR Convergence 2020
Reducing Immunogenicity of Pegloticase (RECIPE) with Concomitant Use of Mycophenolate Mofetil in Patients with Refractory Gout—a Phase II Double Blind Randomized Controlled Trial
Background/Purpose: Pegloticase, a recombinant, pegylated uricase, is used for treatment of gout in patients who fail oral urate lowering therapy (ULT). Despite successful reduction of…Abstract Number: 0652 • ACR Convergence 2020
Changes in Serum Urate, in the First 6-months of Initiation or Change of Urate-Lowering Therapy, Associate with Immediate Health-Related Quality of Life Outcomes in People with Gout
Background/Purpose: Few studies, if any, have found association of the biochemical cause of gout (high serum urate) with functional limitation and health-related quality of life…Abstract Number: 0953 • ACR Convergence 2020
Long-term Xanthine Oxidase Inhibitor Treat to Target Urate Lowering Therapy Coordinately Re-wires the Mononuclear Leukocyte Mitochondrial and Inflammatory Proteome in Gout
Background/Purpose: In gout, long-term xanthine oxidase inhibitor treat to target urate lowering therapy (XOIT2T) markedly reduces flares and synovitis, despite delayed resolution of tissue crystal…Abstract Number: 0654 • ACR Convergence 2020
The Effects of Dietary Macronutrients on Serum Urate: A Secondary Analysis of the OmniHeart Trial
Background/Purpose: Diet is a significant determinant of hyperuricemia and risk for gout. Dietary recommendations to prevent gout emphasize reducing purine intake; however, low-purine diets are…Abstract Number: 1472 • ACR Convergence 2020
Assessing Causal Associations of Urate Levels with Type 2 Diabetes and Related Glycemic Traits Using Bidirectional Mendelian Randomization
Background/Purpose: Type 2 diabetes (T2D) and gout/hyperuricemia frequently coexist, but the nature and direction of this relationship is unclear. Observational studies have reported positive associations…Abstract Number: 0655 • ACR Convergence 2020
Weight Loss as Treatment for Gout in Patients with Concomitant Obesity: A Proof-of-Concept Randomized Controlled Trial
Background/Purpose: Despite scarce evidence regarding the effects of weight loss in gout1, international guidelines recommend dietary advice and weight loss as a core management strategy…Abstract Number: 1628 • ACR Convergence 2020
Management of Gout After Pegloticase; Observations of US Clinical Practice from Trio Health and the American Rheumatology Network (ARN)
Background/Purpose: Pegloticase is approved for severe gout in patients that are intolerant to, or whose disease is ineffectively controlled by, other uric acid lowering therapies…Abstract Number: 0658 • ACR Convergence 2020
Identification of Two Novel Dysfunctional Variants in a Physiologically Important Urate Transporter ABCG2 in Paediatric-onset Familial Hyperuricemia and Gout Patients in Three Generations
Background/Purpose: ABCG2 is a high-capacity urate transporter gene. Common dysfunctional variants of ABCG2 that result in decreased urate excretion in humans are major causes of…Abstract Number: 1629 • ACR Convergence 2020
Management of Gout with Pegloticase; Real-World Utilization and Outcomes from Trio Health and the American Rheumatology Network (ARN)
Background/Purpose: Infusion reactions and other adverse events associated with pegloticase may lead to discontinuation of treatment in patient populations that have already failed or are…Abstract Number: 0659 • ACR Convergence 2020
Polynesian-Specific Gout-Associated Frameshift Variant in PRPSAP1
Background/Purpose: Polynesian (NZ Māori and Pacific) populations have increased prevalence of gout. Hyperuricaemia is contributed to by increased urate production in the liver via the…
ACR Meeting Abstracts